Security key
17331Y109
CITIUS ONCOLOGY, INC. - Common Shares, $0.0001 par value per share (CTOR)
CUSIP: 17331Y109
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Shares, $0.0001 par value per share
- Total 13F shares
- 107,424
- Total 13F value
- $69,836
- Share change
- 0
- SEC-reported price per share
- $0.65
- Number of holders
- 1
- Shares outstanding
- 93,027,627
Holder snapshot
3 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
1
Top holders
1
CTOR full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
CITIUS ONCOLOGY, INC. SEC filings
CITIUS ONCOLOGY, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 17331Y109
Recent filing periods:
Ownership snapshot
Top reported holders of CTOR - CITIUS ONCOLOGY, INC. - Common Shares, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Citius Pharmaceuticals, Inc.
Disclosed value leader
Citius Pharmaceuticals, Inc.
Comparable rows
14/15
Latest evidence
15 May 2026
13D/G
3/4/5
13F
Lead comparable stake: 71%
1 rows are not safely comparable across share classes.
13D/G row: Citius Pharmaceuticals, Inc.
Showing 1-6 of 15 holder rows.
Quick read
Citius Pharmaceuticals, Inc. leads the comparable SEC ownership view at 71%.
14 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Citius Pharmaceuticals, Inc.'s linked filing trail.
Comparable ownership
Top 5
Citius Pharmaceuticals, Inc.
71%
ARMISTICE CAPITAL, LLC
10%
BANK OF AMERICA CORP /DE/
4.1%
VANGUARD CAPITAL MANAGEMENT LLC
0.57%
GEODE CAPITAL MANAGEMENT, LLC
0.28%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. |
13D/G
3/4/5
10%+ Owner
|
71%
|
$59,444,654
66,049,615 shares
|
$0 | 15 May 2026 |
| ARMISTICE CAPITAL, LLC |
13D/G
13F
Company
|
10%
|
$6,044,946
9,299,917 shares
|
+$793,983 | 31 Mar 2026 |
| BANK OF AMERICA CORP /DE/ |
13F
Company
|
4.1%
|
$2,373,964
3,835,160 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
0.57%
|
$331,591
534,824 shares
|
— | 31 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.28%
|
$164,107
264,733 shares
|
— | 31 Mar 2026 |
| VANGUARD FIDUCIARY TRUST CO |
13F
Company
|
0.13%
|
$75,584
121,910 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
107,424
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
13
Q2 2026 holders
1
Holder diff
-12
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend